Branded Differin has annual US sales of $91 million.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has obtained US Food and Drug Administration (FDA) for its generic version of acne gel, Differin, made by Switzerland's Galderma Laboratories. Teva has begun the commercial launch of the product.
Brand Differin has annual US sales of $91 million, according to IMS sales data.
Teva's share closed at $54.28 on Nasdaq yesterday, and rose 0.1% in early trading on the TASE today to NIS 209.30.
Published by Globes [online], Israel business news - www.globes-online.com - on June 3, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010